A combination of cross-neutralizing antibodies synergizes to prevent SARS-CoV-2 and SARS-CoV pseudovirus infection

Mostrar otras versiones (1)

Coronaviruses have caused several human epidemics and pandemics including the ongoing coronavirus disease 2019 (COVID-19). Prophylactic vaccines and therapeutic antibodies have already shown striking effectiveness against COVID-19. Nevertheless, concerns remain about antigenic drift in SARS-CoV-2 as...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Hejun, Yuan, Meng, Huang, Deli, Bangaru, Sandhya, Zhao, Fangzhu, Lee, Chang-Chun D., Peng, Linghang, Barman, Shawn, Zhu, Xueyong, Nemazee, David, Burton, Dennis R., van Gils, Marit J., Sanders, Rogier W., Kornau, Hans-Christian, Reincke, S. Momsen, Prüss, Harald, Kreye, Jakob, Wu, Nicholas C., Ward, Andrew B., Wilson, Ian A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cell Press 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049401/
https://www.ncbi.nlm.nih.gov/pubmed/33894127
http://dx.doi.org/10.1016/j.chom.2021.04.005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8049401/
https://www.ncbi.nlm.nih.gov/pubmed/33894127
http://dx.doi.org/10.1016/j.chom.2021.04.005

Ejemplares similares